Published on 6 Nov 2023 on GuruFocus.com via Yahoo Finance
Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update
Black Diamond Therapeutics Inc (NASDAQ:BDTX) reported Q3 2023 financial results, with a net loss of $23.0 million compared to $21.7 million in the same period in 2022.The company's cash, cash equivalents, and investments stood at $144.3 million as of September 30, 2023, up from $122.8 million as of December 31, 2022.Research and development expenses increased slightly to $16.2 million from $15.8 million in Q3 2022, primarily due to the advancement of the company's pipeline programs.General and administrative expenses rose to $7.9 million from $6.3 million in the same period in 2022, mainly due to costs related to the transition of its former President and CEO.
Warning! GuruFocus has detected 2 Warning Signs with BDTX.